Unibest
← Back to patent-cliff list

CAS 2986-19-8

methyl carbamimidothioate

Codes: AVAN-002, DECI-002, AZAC-002

Application context (from source-drug indications)

Erectile dysfunctionAvanafilAllergic reactionDecitabineCycloplegiaDecitabineHypotensionDecitabineAcute myeloid leukaemiaDecitabineMyelodysplastic syndromeDecitabineDiffuse large B-cell lymphomaDecitabine幼年型粒单核细胞白血病AzacitidineAcute myeloid leukaemiaAzacitidineMyelodysplastic syndromeAzacitidineChronic myeloid leukaemiaAzacitidineChronic myelomonocytic leukaemiaAzacitidine脑性瘫痪Azacitidine

Source drugs (routes using this intermediate)

DrugTierExpiry
AvanafilTier C — Watch / trade2028
DecitabineTier C — Watch / trade-
AzacitidineTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

DecitabineOriginator routesteps: 3total yield: 1.65 g
((2R,3S)-3-acetoxy-5-isocyanatotetrahydrofuran-2-yl)methyl acetate→methyl carbamimidothioate→((2R,3S)-3-acetoxy-5-(3-((E)-amino(methylthio)methylene)ureido)tetrahydrofuran-2-yl)methyl acetate→methanetriol→((2R,3S,5R)-3-acetoxy-5-(4-(methylthio)-2-oxo-1,3,5-triazin-1(2H)-yl)tetrahydrofuran-2-yl)methyl acetate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.